R397
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 42
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- E2F_TARGETS+0.540
- G2M_CHECKPOINT+0.470
- PANCREAS_BETA_CELLS+0.420
- SPERMATOGENESIS+0.360
- MTORC1_SIGNALING+0.310
- MYC_TARGETS_V1+0.290
- ANDROGEN_RESPONSE+0.250
- MITOTIC_SPINDLE+0.220
- PROTEIN_SECRETION+0.220
- CHOLESTEROL_HOMEOSTASIS+0.200
Top 10 suppressed
- WNT_BETA_CATENIN_SIGNALING-0.490
- TGF_BETA_SIGNALING-0.440
- ALLOGRAFT_REJECTION-0.420
- IL6_JAK_STAT3_SIGNALING-0.420
- NOTCH_SIGNALING-0.420
- TNFA_SIGNALING_VIA_NFKB-0.380
- INTERFERON_GAMMA_RESPONSE-0.360
- INTERFERON_ALPHA_RESPONSE-0.350
- P53_PATHWAY-0.330
- INFLAMMATORY_RESPONSE-0.300
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | GSM5359415 | — | — | 0.814 |
| 2 | R360 | — | — | 0.788 |
| 3 | MDT-AP-3082 | Med | Medulloblastoma | 0.785 |
| 4 | SRR13780262 | — | cohortSC | 0.783 |
| 5 | R239 | — | — | 0.776 |
| 6 | DRR168591 | — | — | 0.771 |
| 7 | SAMN03290890 | — | — | 0.771 |
| 8 | SRR5088861 | — | — | 0.768 |
| 9 | R391 | — | — | 0.765 |
| 10 | R55 | — | — | 0.763 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 23 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| E2F_TARGETS | 0.540 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.470 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.420 | Cobimetinib | — uncovered |
| SPERMATOGENESIS | 0.360 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.310 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.290 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.250 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.220 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.220 | Remibrutinib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.200 | Remibrutinib | — uncovered |
| BILE_ACID_METABOLISM | 0.190 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.190 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.130 | Idelalisib | — uncovered |
| PEROXISOME | 0.120 | Idelalisib | — uncovered |
| UV_RESPONSE_DN | 0.120 | Inavolisib | — uncovered |
| HYPOXIA | 0.110 | Idelalisib | — uncovered |
| KRAS_SIGNALING_DN | 0.090 | Remibrutinib | — uncovered |
| APICAL_SURFACE | 0.070 | Temsirolimus | — uncovered |
| GLYCOLYSIS | 0.070 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.050 | Inavolisib | — uncovered |